Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Chritterson Aug 24, 2021 4:33pm
92 Views
Post# 33756165

RE:RE:Emergency use Authorization and what it would mean for CLAS

RE:RE:Emergency use Authorization and what it would mean for CLASAmen!!

Whyme16 wrote: This would be applicable to a REAL company that has a reputation to actually DELIVER! When was the last time this company delivered smething of value?? Phase 1 completion has already been delayed to EARLY 2022 (THIS WAS SUPPOSED TO COMPLETE IN 2021). By the time pahse 2a is completed late 2022 this drug will either be irrelevant OR licence transfered to some other company due to Bob's incompetence and side-deals just like GHVO program. BOB HAS TO RESIGN AND THAT WOULD BE OUR ONLY HOPE OF SURVIVAL.


<< Previous
Bullboard Posts
Next >>